News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chiltern International Ltd. Announces Strong Financial Performance of the Group


6/10/2013 9:57:57 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LONDON and WILMINGTON, N.C., June 10, 2013 /PRNewswire/ -- Chiltern International Group Limited (Chiltern), a global contract research organization (CRO), announces a record financial performance for the fiscal year ended Mar 31, 2013.

  • Revenues of £104 million, a growth of 16.8% from prior year and a CAGR of 15.3% for 2008-2013
  • EBITDA* of £14.9 million, 33% ahead of March 2012 and a CAGR of 19.2% for 2008-2013
  • Backlog of £203 million, up from £187 million at the end of March 2012
  • New business awards of £150 million representing a gross-book-to-bill of 1.5 and a net-book-to-bill of 1.2
  • Chiltern's workforce reached 1,600 people worldwide, which includes further investments in our operations and therapeutic leadership teams

Dr Jim Esinhart, CEO of Chiltern commented: "I am delighted to report that demand for our services is at an all time high. We have delivered over 15% CAGR revenue growth over the last five years which means Chiltern is increasing its market share. We feel customers are actively looking for mid-tier global alternatives with the ability to deliver better value and a comprehensive range of high quality services."

Key to Chiltern's success has been the company culture, built on offering customers flexibility, responsiveness and distinctive innovations coupled with trusted relationships. By attracting the most qualified people in the pharma/biotech/medical device industries, Chiltern has implemented leading resourcing solutions including Functional Service Provision, best-in-class technologies and therapeutically focused clinical research offerings.

"We are proud to say that Chiltern has successfully provided program management and clinical development services for over 30 years, and we see growth continuing as we look ahead. At the same time, it is important that we thank our customers for their support, and credit our dedicated staff for their unwavering focus on quality management and therapeutic and operational expertise," Esinhart added.

Outlook

As we look ahead, we see continued growth for the remainder of the calendar year and beyond. We are confident that our investments in people, in the development of innovative processes and technologies along with our focus in establishing strategic partnerships with our customers have prepared Chiltern for a period of substantial growth and to drive the company forward.

Note

EBITDA* is before exceptional items, minority interest and foreign exchange effects

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com.

For more information contact:



Natalie Chong

Susan Ojanen

Marketing Director

Marketing Executive

Chiltern International Ltd.

Chiltern International Inc.

171 Bath Road

1241 Volunteer Parkway

Slough

Suite 950

Berkshire SL1 4AA

Bristol, TN 37620

UNITED KINGDOM

USA

Tel: +44 (0) 1753 512 000

Tel: +1 (423) 968 9533

Fax: +44 (0) 1753 511 116

Fax: +1 (423) 968 3567

Email: natalie.chong@chiltern.com

Email: susan.ojanen@chiltern.com



For financial enquiries contact:



Dineen

Ben Atwell

Senior Director

Senior Managing Director

FTI Consulting

FTI Consulting

Holborn Gate

Holborn Gate

26 Southampton Buildings

26 Southampton Buildings

London WC2A 1PB

London WC2A 1PB

UNITED KINGDOM

UNITED KINGDOM

Tel: +44 (0) 20 7269 7193 direct

Tel: +44 (0) 20 7269 7242 direct

Fax: +44 (0) 203 077 0519

Fax: +44 (0) 203 077 0519

Email: John.Dineen@fticonsulting.com

Email: Ben.Atwell@fticonsulting.com

SOURCE Chiltern International



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES